Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03197779 · ClinicalTrials.gov registry record · Phase 1
A Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-962212 in Healthy Subjects
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 691
- Enrollment target
NCT03197779: Completed Phase 1 study, sponsored by Bristol-Myers Squibb.
NCT03197779 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 691 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (1052% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03197779, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 691 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics following increasing doses of 2 h (Part A) and 5 day (Part B) continuous IV infusions of BMS-962212 in healthy subjects across the expected pharmacodynamic dose range.
Primary Outcome
measured by incidence
Interventions
- OTHER Placebo
- DRUG Aspirin
- DRUG BMS-962212
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 691 participants |
| Start Date | 2013-11-18 |
| Est. Completion | 2017-01-24 |
| Phase | Phase 1 |
What the finished NCT03197779 record still lists
NCT03197779 is an interventional study that assigns participants to a tested intervention. The registered 691 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (1052% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03197779 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03197779 about?
NCT03197779 is a clinical study titled "A Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-962212 in Healthy Subjects". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics following increasing doses of 2 h (Part A) and 5 day (Part B) continuous IV infusions of BMS-962212 in healthy subjects across the expected pharmacodynamic dose range.
What is the current status of trial NCT03197779?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 691 participants. The study started on 2013-11-18. Estimated completion is 2017-01-24.
What interventions are being tested in trial NCT03197779?
The interventions under investigation include: Placebo (OTHER), Aspirin (DRUG), BMS-962212 (DRUG).
Who is sponsoring clinical trial NCT03197779?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03197779's enrollment target sits among peer trials
691 21st of 2000 higher than 1,980 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07382167 · 692 participants · Phase 3
A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults
- NCT00532051 · 690 participants
Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence Tomography
- NCT05184335 · 690 participants · Phase 3
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
- NCT07221149 · 690 participants · Phase 2
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI